CD41a Monoclonal Antibody (HIP8), FITC, eBioscience™, Invitrogen™

Description

• Description: The HIP8 monoclonal antibody reacts with the human CD41 molecule, the integrin alphaIIb also known as platelet GPIIb
• CD41 non-covalently associates with integrin beta3 (GPIIIa, CD61) and is expressed by megakaryocytes and platelets
• The CD41/CD61 complex is a receptor for fibronectin, fibrinogen, von Willebrand factor, vitronectin and thrombospondin and mediates platelets aggregation
• HIP8 blocks platelet aggregation
• Applications Reported: The HIP8 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This HIP8 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.25 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD41 (platelet glycoprotein IIb, ITGA2B) is composed of two subunits -120 kDa a, alpha and 23 kDa b, beta- that interact with CD61 in the presence of calcium to form a functional adhesive protein receptor
• CD41 is also involved in blood coagulation by mediating platelet aggregation
• Upon blood vessel damage, CD41 binds to a variety of proteins including von Willebrand factor, fibrinogen, fibronectin and vitronectin
• CD41 is mainly expressed on megakaryocyte-platelet lineage, but generally belongs to the antigens that are expressed during the early stages of hematopoietic differentiation
• Diseases associated with CD41 dysfunction include Glansmann Thrombasthenia, and Platelet type-16 bleeding disorder.